IGF-1 LR3 vs SNAP-8
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →SNAP-8
SNAP-8 (Acetyl Octapeptide-3) is a cosmetic peptide that reduces the appearance of wrinkles by modulating muscle contraction. It is often called 'topical Botox' though it works through a different mechanism.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | SNAP-8 |
|---|---|---|
| Dose Range | 20 mcg–100 mcg | 500 mcg–1 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–6 weeks | 4–8 weeks |
| Route | subcutaneous | topical |
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Mimics the N-terminal end of SNAP-25, competing with native SNAP-25 for position in the SNARE complex. This reduces neurotransmitter release at the neuromuscular junction, decreasing muscle contraction. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Topical: 3-10% concentration in serums or creams, applied 1-2 times daily to target areas (forehead, crow's feet, etc.). |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Topical application only. Should be applied to clean skin. Often formulated with penetration enhancers for better absorption. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Generally well-tolerated topically. Rare reports of mild skin irritation. No systemic effects at cosmetic doses. |
| Best For |
Key Differences
Unique to IGF-1 LR3:
Unique to SNAP-8:
Key Studies
IGF-1 LR3
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
American journal of physiology. Endocrinology and metabolism, 2025
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.
International journal of biological macromolecules, 2025
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
Journal of developmental origins of health and disease, 2023
Ready to Learn More?
Looking for trusted sources?